

Haematologica  
HAEMATOL/2014/120816  
Version 3

Pulmonary arterial hypertension exacerbated by ruxolitinib

Disclosures: AL and LH have no conflicts of interest to declare. CH has received research funding and honoraria including speaker fees from Novartis pharmaceuticals. RT has received educational grants and speaker fees from Pfizer, Actelion, Encysive and GSK.

Contributions: All authors contributed equally to this work.